Targets › PIK3R2
2 programs from 2 companies in 9 trials: 5 Phase 2, 4 Phase 1; Oncology, Other; next expected readout Feb 2027.
Regulatory subunit of phosphoinositide-3-kinase (PI3K), a kinase that phosphorylates PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. (UniProt, O00459)
Open in Phaseline: the race on PIK3R2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Taselisib (GDC-0032) PI3-kinase class I inhibitor | PIK3R1, PIK3CB, PIK3CG, PIK3CA, PIK3R2 | Phase 2 | Advanced Lymphoma | Mar 2027 |
| Sovargen | Paxalisib (SVG103) PI3-kinase class I inhibitor | PIK3R1, PIK3CB, PIK3CG, PIK3CA, PIK3R2 | Phase 1 | Focal Cortical Dysplasia; Primary Central Nervous System Lymphoma; Glioblastoma; CDK Gene Mutation … | Feb 2027 |
Advanced Lymphoma (1) Focal Cortical Dysplasia (1) Primary Central Nervous System Lymphoma (1) Glioblastoma (1) CDK Gene Mutation (1) Recurrent Atypical Teratoid/Rhabdoid Tumor (1) Brain Metastases (1) Malignant Primary Gliomas (1) Childhood Cancer (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.